参考文献/References:
[1].Ibanez B,James S,Agewall S,et al.2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) [ J].Eur Heart J,2018,39(2):119-177.
[2].Levine GN,Bates ER,Blankenship JC,et al.2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction:An Update of the 2011 ACCF/AHA/SCAI?Guidelinefor Percutaneous Coronary Intervention and the 2013 ACCF/AHA?Guideline?for the Management of ST-Elevation Myocardial Infarction[J].J Am Coll Cardiol,2016,67(10):1235-1250.
[3].卫训,汪凤仪.双重抗血小板治疗稳定型缺血性心脏病[J].心血管病学进展,2018,39(6):1056-1060.
[4].Miyazaki Y,Suwannasom P,Sotomi Y,et al.Single or?dual?antiplatelet?therapy?after PCI[J]. Nat Rev Cardiol ,2017,14(5):294-303.
[5].韩雅玲.冠心病抗血小板治疗的新潮流:降阶治疗[J].中华心血管病杂志,2019,47(10):759-761.
[6].Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018?ESC/EACTS Guidelines on?myocardial revascularization[J]. Eur Heart J ,2019,40(2):87-165.
[7].中华医学会心血管病学分会介入心脏病学组.中国经皮冠状动脉介入治疗指南(2016) [ J].中华心血管病杂志,2016,44(5):382-400.
[8].Yeh RW,Kereiakes DJ,Steg PG,et al.Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction[J].J Am Coll Cardiol,2015,65(20):2211-2221.
[9].Bonaca MP,Storey RF,Theroux P,et al.Efficacy and safety of ticagrelor over?time in patients with prior MI in?PEGASUS-TIMI?54[J].J Am Coll Cardiol,2017,70(11):1368-1375.
[10].Lee CW,Ahn JM,Park DW,et al.Optimal?duration?of?dual?antiplatelet?therapy?after?drug-eluting stent implantation:a randomized,controlled trial[J].Circulation,2014,129(3):304-312.
[11].Collet JP,Silvain J,Barthélémy O,et al.Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption):a randomised trial[J].Lancet,2014,384(9954):1577-1585.
[12].Elmariah S,Mauri L,Doros G,et al.Extended?duration?dual antiplatelet therapy and mortality:a systematic review and meta-analysis[J].Lancet,2015,385(9970):792-798.
[13].Gwon HC,Hahn JY,Park KW,et al.Six month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents:the Efficacy of Xience/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized,multicenter study[J].Circulation,2012,125(3):505-513.
[14].Colombo A,Chieffo A,Frasheri A,et al.Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy:the SECURITY randomized clinical trial[J].J Am Coll Cardiol,2014,64(20):2086-2097.
[15].Schulz-Schupke S,Byrne RA,Ten Berg JM,et al.ISAR-SAFE:a randomized,double-blind,placebo-controlled trial of 6 vs.12 months of clopidogrel therapy after drug-eluting stenting[J].Eur Heart J,2015,36(20):1252-1263.
[16].Han Y,Xu B,Xu K,et al.Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent:randomized substudy of the?I-LOVE-IT?2?trial[J].Circ Cardiovasc Interv,2016,9(2):e003145.
[17].Hahn JY,Song YB,Oh JH,et al.6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE):a randomised,open-label,non-inferiority?trial[J]. Lancet ,2018,391(10127):1274-1284.
[18].Gilard M,Barragan P,Noryani AA,et al.6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin:the randomized, multicenter ITALIC trial [J].J Am Coll Cardiol,2015,65(8):777-786.
[19].Valgimigli M,Campo G,Monti M,et al.Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting:a randomized multicenter trial[J].Circulation,2012,125(16):2015-2026.
[20].Feres F,Costa RA,Abizaid A,et al.Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents:the OPTIMIZE randomized trial[J].JAMA,2013,310(23):2510-2522.
[21].Kim BK,Hong MK,Shin DH,et al.A new strategy for discontinuation of dual antiplatelet therapy:the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimuseluting stent implantation) [ J].J Am Coll Cardiol,2012,60(15):1340-1348.
[22].Palmerini T,Della Riva D,Benedetto U,et al.Three,six,or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes:an individual patient data pairwise and network meta-analysis of six randomized trials and 11?473 patients[J]. Eur Heart J ,2017,38(14):1034-1043.
[23].Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA Guideline Focused?Update on?Duration?of Dual?Antiplatelet Therapy in Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task?Force?on?Clinical Practice Guidelines[J]. J Am Coll Cardiol ,2016,68(10):1082-115.
[24].Gaziano JM,Brotons C,Coppolecchia R,et al .Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE):a randomised, double-blind ,placebo-controlled?trial[J]. Lancet ,2018,392(10152):1036-1046.
[25].McNeil JJ,Nelson MR,Woods RL,et al.Effect of aspirin on all-cause mortality in the healthy elderly[J]. N Engl J Med ,2018,379(16):1519-1528.
[26].Bowman L,Mafham M,Wallendszus K,et al.Effects of aspirin for primary prevention in persons with diabetes mellitus[J]. N Engl J Med ,2018,379(16):1529-1539.
[27].Abdelaziz HK,Saad M,Pothineni NVK,et al .Aspirin for primary prevention of cardiovascular events[J].J Am Coll Cardiol,2019,73(23):2915-2929.
[28].Vranckx P,Valgimigli M,Jüni P,et al.Ticagrelor plus aspirin for 1 month,followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicentre ,open-label,randomised superiority?trial[J]. Lancet ,2018,392(10151):940-949.
[29].Franzone A,McFadden E,Leonardi S,et al.Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting[J].J Am Coll Cardiol,2019,74(18):2223-2234.
[30].Watanabe H,Domei T,Morimoto T,et al.Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI:The STOPDAPT-2 Randomized clinical trial [J].JAMA,2019,321(24):2414-2427.
[31].Hahn JY,Song YB,Oh JH,et al.Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention:the SMART-CHOICE randomized?clinical?trial[J].JAMA,2019,321(24):2428-2437.
[32].Mehran R,Baber U,Sharma SK,et al.Ticagrelor with or without aspirin in High-Risk Patients after PCI[J]. N Engl J Med ,2019,381(21):2032-2042.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(10):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(10):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(10):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(10):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(10):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(10):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(10):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(10):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(10):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(10):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]